

PRESCRIPTION DRUG AFFORDABILITY BOARD MEETING

Monday, October 28, 2024

Minutes

Chair Van Mitchell called the meeting to order at 2:00 p.m.

Board Members present: Van Mitchell, Gerard Anderson, Ph.D., Eberechukwu Onukwugha, MS, Ph.D., Joseph Levy, Ph.D., Stephen Rockower, MD

AGENDA ITEM 2

Approval of minutes

Chair Mitchell asked for a motion to approve the September 10, 2024 meeting minutes as submitted. Dr. Gerald Anderson made the motion, which Dr. Stephen Rockower seconded, and the Board unanimously approved the minutes.

Action: Minutes APPROVED.

AGENDA ITEM 3

Opportunity for Public Comment

One written comment was received which was provided to the Board and posted to the website. One person registered for oral public comment but they were not present at the meeting.

AGENDA ITEM 4

Upper Payment Limit Action Plan- Update

Executive Director Andrew York provided a verbal update on the Upper Payment Limit Action Plan. The Legislative Policy Committee approved the Upper Payment Limit Action Plan on October 22, 2024 with a 15-5 vote.

PDAB staff have posted draft proposed regulations regarding Upper Payment Limits to the Board's website. Written public comment on these draft regulations are due on November 8, 2024. PDAB staff will provide a timeline to the Board regarding these regulations.

Dr. York asked for the Board's input on moving forward with the UPL's monitoring plan; specifically, what should staff monitor for and what should be done as part of the monitoring plan. Discussion took place around this topic with Board member input. Additionally, Dr. York explained that the UPL Action Plan will allow for reconsideration and add a new set of hearing procedures that allow for additional public comment opportunities.

AGENDA ITEM 5

Cost Review Study Process- Update

Executive Director Andrew York provided a verbal update on the Cost Review Study Process. The following pertinent information was mentioned:

- The PDAB is accepting public comments for prescription drug products which have gone through the RFI process (i.e., Jardiance, Farxiga, Ozempic, Trulicity) until Friday, November 8, 2024. The PDAB hopes to obtain more comments around patient and clinician experiences.
- At a prior meeting, the Board proposed amending certain cost review study regulations. The proposed amendments were submitted as emergency regulations to AELR and to the Division of State Documents for publication in the Maryland Register. . The request for emergency status remains pending with AELR. The proposed regulations will be published in the November 1, 2024 Maryland Register, and the Board will accept public comment for 30-days ending December 2, 2024. Information will be posted on the PDAB website when available.
- The Board received several RFI submissions from various entities and would like to express their appreciation.
- There was a Board discussion around the cost review study process data and analysis, specifically around disease burden and obtaining additional data.

AGENDA ITEM 6

Administrative Update

- PDAB staff will send second notices for the FY25 fee assessment in the near future.
- The next PDASC meeting will take place on Monday, November 4, 2024. This meeting will focus on obtaining stakeholder council feedback on the draft Upper Payment Limit regulations.
- Dr. York provided an update on the State of Maryland pharmacy benefit manager procured through the reverse auction process.

AGENDA ITEM 7

Chair's Update

- Chairman Mitchell expressed gratitude toward the PDASC for their scheduling flexibility, Jim Johnson for his instrumental work in assisting the Board with finances, and MHBE for providing PDAB staff essential services.
- The next PDAB meeting will be on Monday, November 25, 2024 at the Miller Senate Building in Annapolis at 2:00 PM.

AGENDA ITEM 8

Adjournment

Chair Mitchell asked for a motion to adjourn the meeting. Dr. Anderson made the motion to adjourn, which was seconded by Dr. Onukwugha.

Adjourned at 2:47 PM